CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma
Crossref DOI link: https://doi.org/10.1007/s00262-015-1675-7
Published Online: 2015-03-10
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kumai, Takumi
Nagato, Toshihiro
Kobayashi, Hiroya
Komabayashi, Yuki
Ueda, Seigo
Kishibe, Kan
Ohkuri, Takayuki
Takahara, Miki
Celis, Esteban
Harabuchi, Yasuaki
Text and Data Mining valid from 2015-03-10